Perlegen and 454 Embark On Drug Response Sequencing Study
Companies seek to ascertain the role of genetic variations in patients’ reaction to a particular class of medications.
Perlegen Sciences and 454 Life Sciences are collaborating to conduct large-scale genetic resequencing in human DNA samples collected by Perlegen from individuals with specific responses to a widely prescribed class of drug. The goal is to determine whether sufficient genetic variation can be identified and validated to create a test to predict how individuals may respond to these types of medications.
Perlegen and 454 will each resequence select portions of the genome within each sample. The study will use 454 Sequencing™ technology and Perlegen's sample preparation and amplification tools. Data analysis teams from both firms together will study the results to determine how significant a role variations in genetic sequence play in patient response to this drug class.